Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs
- PMID: 17189244
- DOI: 10.1093/rheumatology/kel393
Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs
Abstract
Objective: To assess safety and efficacy of repeated B-cell depletion with rituximab in patients with rheumatoid arthritis (RA).
Methods: Thirty-seven patients with refractory RA entered into a programme of repeated B-lymphocyte depletion (up to 5 cycles, 89 cycles in total) with protocols based on the anti-CD20 monoclonal antibody, rituximab, have been observed over periods of >5 yrs (n = 22) or 3-5 yrs (n = 14).
Results: Twenty two subjects have been followed up for >5 yrs. Average duration of benefit per cycle was 15 months (maximum 43 months), and time to re-treatment 20 months. Nineteen patients remain on the programme. Patients were withdrawn for lack of efficacy (n = 5), hypersensitivity infusion reaction (n = 1), brevity of response (n = 8), or occurrence of adverse respiratory events (n = 1). Sixteen major lower respiratory events occurred during the 180 patient-yrs of follow-up. Of these only one had low IgG. In patients receiving rituximab +/- cyclophosphamide (cy) carcinomata have developed as follows: breast (3, +cy), ovary (1, +cy), transitional cell (1, +cy), and renal cell (1, -cy). Falls in total immunoglobulin levels to below the normal range occurred in 12 patients for IgM (undetectable levels in three after repeated cycles), seven for IgG and one for IgA, not taking into account patients who started off with low immunoglobulin levels before the first cycle.
Conclusion: Repeated B-lymphocyte depletion over a 5-yr period appears to be an acceptable and relatively well-tolerated therapy in RA with a relatively high rate of continuation. Long-term effects on immunoglobulin levels require surveillance.
Similar articles
-
Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis.Arthritis Rheum. 2003 Aug;48(8):2146-54. doi: 10.1002/art.11181. Arthritis Rheum. 2003. PMID: 12905467
-
Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment.J Rheumatol. 2005 Nov;32(11):2109-15. J Rheumatol. 2005. PMID: 16265687 Clinical Trial.
-
Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis.Arthritis Rheum. 2006 Feb;54(2):613-20. doi: 10.1002/art.21617. Arthritis Rheum. 2006. PMID: 16447239
-
Long-term effects of rituximab in rheumatoid arthritis: clinical, biologic, and pharmacogenetic aspects.Ann N Y Acad Sci. 2009 Sep;1173:692-700. doi: 10.1111/j.1749-6632.2009.04668.x. Ann N Y Acad Sci. 2009. PMID: 19758217 Review.
-
B lymphocyte depletion therapy with rituximab in rheumatoid arthritis.Rheum Dis Clin North Am. 2004 May;30(2):393-403, viii. doi: 10.1016/j.rdc.2004.01.006. Rheum Dis Clin North Am. 2004. PMID: 15172048 Review.
Cited by
-
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.Ann Rheum Dis. 2011 Jun;70(6):909-20. doi: 10.1136/ard.2010.144998. Epub 2011 Mar 6. Ann Rheum Dis. 2011. PMID: 21378402 Free PMC article.
-
Living life without B cells: is repeated B-cell depletion a safe and effective long-term treatment plan for rheumatoid arthritis?Int J Clin Rheumtol. 2012 Apr 1;7(2):159-166. doi: 10.2217/ijr.12.7. Int J Clin Rheumtol. 2012. PMID: 22792128 Free PMC article.
-
Translational Mini-Review Series on B Cell-Directed Therapies: B cell-directed therapy for autoimmune diseases.Clin Exp Immunol. 2009 Aug;157(2):181-90. doi: 10.1111/j.1365-2249.2009.03977.x. Clin Exp Immunol. 2009. PMID: 19604257 Free PMC article. Review.
-
Rituximab in induction therapy for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis.Clin Exp Immunol. 2011 May;164 Suppl 1(Suppl 1):27-30. doi: 10.1111/j.1365-2249.2011.04363.x. Clin Exp Immunol. 2011. PMID: 21447128 Free PMC article. Review.
-
JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis.Front Med (Lausanne). 2021 Feb 5;7:607725. doi: 10.3389/fmed.2020.607725. eCollection 2020. Front Med (Lausanne). 2021. PMID: 33614673 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous